US2017037139A1PendingUtilityA1

Treatment of diffuse large-cell lymphoma with anti-cd20 antibody

58
Assignee: BIOGEN INCPriority: Aug 11, 1999Filed: Oct 25, 2016Published: Feb 9, 2017
Est. expiryAug 11, 2019(expired)· nominal 20-yr term from priority
Inventors:Christine A. WhiteAntonio J. Grillo-Lopez
A61P 35/00A61K 31/475A61K 31/573A61K 31/664A61K 31/675C07K 16/2887A61K 31/704A61K 39/39558Y10S424/801A61K 2039/505A61K 35/28C07K 2317/24A61K 39/3955A61K 35/545
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.

Claims

exact text as granted — not AI-modified
1 . A method of treating a patient with diffuse large cell lymphoma comprising administering a therapeutically effective amount of an anti-CD20 antibody and chemotherapy to the patient. 
     
     
         2 . The method of  claim 1 , wherein the anti-CD20 antibody comprises a chimeric antibody. 
     
     
         3 . The method of  claim 2 , wherein the anti-CD20 antibody comprises rituximab. 
     
     
         4 . The method of  claim 1 , wherein the chemotherapy comprises CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone). 
     
     
         5 . The method of  claim 4 , wherein the anti-CD20 antibody and CHOP are administered simultaneously. 
     
     
         6 . The method of  claim 5 , wherein the anti-CD20 antibody and CHOP are administered concurrently. 
     
     
         7 . The method of  claim 5 , comprising administering the anti-CD20 antibody on Day 1 of each chemotherapy cycle and the CHOP on Day 1 of each chemotherapy cycle. 
     
     
         8 . A method of treating a human patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the rituximab and the CHOP are administered concurrently. 
     
     
         9 . A method of treating a human patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the rituximab is administered on Day 1 of each chemotherapy cycle and the CHOP is administered on Day 1 of each chemotherapy cycle.

Join the waitlist — get patent alerts

Track US2017037139A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.